Navigation Links
FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Aspergillosis
Date:12/3/2013

aspergillosis is caused by Aspergillus molds and typically affects patients with an impaired or weakened immune system. It is estimated to occur in five to 13 percent of recipients of bone marrow transplants often associated with leukemia, five to 25 percent of patients who have received heart or lung transplants, and 10 to 20 percent of patients who are receiving intensive chemotherapy for leukemia.[3] Mortality rates for transplant patients with invasive aspergillosis have been reported to be between 34 and 58 percent.[4] Zygomycosis is an important emerging fungal infection, associated with high morbidity and mortality. Mortality rates have been reported to be as high as 80 percent in infected transplant patients.[5]

About isavuconazole
Isavuconazole (drug substance: isavuconazonium sulfate) is an investigational once daily intravenous and oral broad-spectrum antifungal for the potential treatment of severe invasive and life-threatening fungal infections. It is currently in phase 3 of clinical development. Isavuconazole demonstrated in-vitro and in-vivo coverage of a broad range of yeasts (such as Candida species) and molds (such as Aspergillus species) as well as activity in in-vitro studies and animal models against emerging and often fatal molds including those that cause zygomycosis. Isavuconazole received U.S. FDA fast-track status and U.S. orphan drug designation for invasive aspergillosis and zygomycosis. Isavuconazole is being co-developed with Basilea Pharmaceutica Ltd.

About the isavuconazole phase 3 program
The phase 3 program with isavuconazole includes three studies, SECURE, VITAL and ACTIVE. Recently, positive topline results were reported from the SECURE study, a global randomized, double-blind phase 3 study, designed to evaluate the safety and efficacy of once-daily isavuconazole versus twice-daily voriconazole in the primary treatment of invasive fungal disease caused by Aspergillus species or certain other filamentous fungi
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. RadSite Grants Accreditation to First Wave of MIPPA Program Applicants
2. NASDAQ Grants China Jo-Jo Drugstores 180-Day Extension to Regain Compliance with Bid Price Requirement
3. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
4. FDA Grants 510(k) Clearance for Innovative Fuse Gastroscope from EndoChoice
5. Philanthropic Grants, Product Launches, Promising Partnerships, and Customer Satisfaction Rankings - Research Report on CVS Caremark, Walgreens, McKesson, AmerisourceBergen, and Cardinal Health
6. Life Technologies Awards Digital PCR Innovation Grants to Five Research Labs
7. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
8. FDA Grants Orphan Drug Designation to Omeros OMS824 for Huntingtons Disease
9. European Union Grants a Good Manufacturing Practice Certificate to Nelson Laboratories
10. The Kenneth Rainin Foundation Continues its Commitment to Ending Inflammatory Bowel Disease, Awarding $1.5 Million in Research Grants
11. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015 Legislation passed today by ... provision to help prevent inappropriate prescriptions in Medicare Part ... the Integrity of Medicare Act (PIMA) of 2014 , ... Kevin Brady (R-TX) and Ranking Member Jim McDermott ... abuse epidemic and implement the right policies, said the ...
(Date:2/26/2015)... February 26, 2015 LifeScienceIndustryResearch.com ... First -In- Class Innovations and Cost Optimization Plays ... Cap Pharmaceutical Companies research report to the pharmaceuticals ... to this Global Pharma US & EU Outlook ... measurements, divestment of non-core assets result in healthy ...
(Date:2/26/2015)...  BD Life Sciences, a segment of BD ... ), a leading global medical technology company, and ... high-resolution biology, today announced that they will be ... cell isolation and single-cell gene expression analysis. ... FACS™ single-cell sorting instrumentation and software with Cellular ...
Breaking Medicine Technology:PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 4BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 3
... SAN FRANCISCO, June 6 OxyBand Technologies Inc., ... the company,s bio-medical,technology development and expand the company,s ... for,health, cosmetic and consumer care. The company,s inaugural ... the FDA for medical and over the,counter marketing. ...
... Data Indicate Overall and Disease-Free Survival -, ... adjuvant trial in,high-risk melanoma patients demonstrated that a ... and/or overall,survival. These findings, which indicate Leukine,s potential ... annual meeting of the American Society,of Clinical Oncology ...
Cached Medicine Technology:OxyBand Technologies, Inc. Hires a Leader in Medical Technology as Chief Technology Officer 2Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 2Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 3Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 4Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 5
(Date:2/27/2015)... MA (PRWEB) February 27, 2015 ... mobility management services, and one of the ... announced support for Bell Mobility within their CLEAN ... of services. Wireless Analytics’ newly developed Bell ... reporting for the Canadian wireless carrier’s business customers. ...
(Date:2/27/2015)... 2015 A new study published in ... men who cycle on a regular basis and prostate cancer. ... suggests that the more hours per week a man spends ... leading to an increased importance on prostate cancer screening methods. ... look more closely at patents’ risk factors for developing prostate ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 ... “cutters”, are often misunderstood, misdiagnosed and therefore ... to healthy lives. Jacksonville-based addiction treatment ... of its highly acclaimed Lakeview Professional Lecture ... interested in understanding this complicated condition. ...
(Date:2/27/2015)... On March 2-4, the Mesothelioma ... Cancer Institute (NCI) will co-host the annual International ... of Health (NIH), in Bethesda, Maryland. The event ... medical professionals and scientists who specialize in mesothelioma, ... public, including patients, their families, and caregivers. , ...
(Date:2/27/2015)... Altec Products, Inc., announced today that ... as their doc-link for Dynamics Partner of the Year. ... solutions for their customers in all different industries with ... and BPW have worked side-by-side to successfully help clients ... , “We are so impressed by the success that ...
Breaking Medicine News(10 mins):Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3
... ATS 2008, TORONTOXScientists believe they may have identified a ... risk of allergy and asthma in childhood. They will ... International Conference in Toronto on Tuesday, May 20., Several ... without allergy at the time of birth. For example, ...
... 21 The Quantum Group,Inc. (Amex: QGP, QGP.WSA, QGP.WSB) ... successfully completed a corporate expansion plan. The Company,increased its ... facility size from 6,600 sq. ft. to 10,600 sq. ... to a larger facility in Doral (west,Miami), Florida., ...
... 21 Crdentia Corp. (OTC Bulletin,Board: CRDT), a leading ... ended March 31, 2008., Revenue in the quarter ... revenue of $9,806,540 and an increase of 31% over ... profit improved to,$2,310,854 in the first quarter of 2008, ...
... ACM today announced a new strategic,alignment that ... next generation technology and services to the two ... commercial plans and,payers, and federal and state governments., ... has been,named EVP/General Manager for Government, and will ...
... sleep apnea (OSA) in very young children may cause ... older children and adults with the condition, according to ... the American Thoracic Societys 2008 International Conference in Toronto ... year of life, said Aviv Goldbart, M.D., the pediatric ...
... that patients with chronic obstructive pulmonary disease (COPD) who ... visits from exacerbations or complications benefit from simple low-intensity ... for COPD was previously shown to reduce hospitalizations for ... a more limited intervention model is effective, said Kathryn ...
Cached Medicine News:Health News:Possible biological explanation for C-Section-linked allergies and asthma found 2Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 2Health News:The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009 3Health News:Crdentia Announces 2008 First Quarter Results 2Health News:Crdentia Announces 2008 First Quarter Results 3Health News:Crdentia Announces 2008 First Quarter Results 4Health News:Crdentia Announces 2008 First Quarter Results 5Health News:Crdentia Announces 2008 First Quarter Results 6Health News:Crdentia Announces 2008 First Quarter Results 7Health News:ACM Taps Two Senior Leaders to Head Up New Strategic Initiatives 2Health News:Low-intensity case management cuts COPD-related hospital visits in half 2
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... Frontier Anterior Deformity System unites the ... Moss Miami, and Isola with revolutionary ... to deliver unsurpassed versatility, simplicity and ... level of versatility for treating a ...
Medicine Products: